Protein tyrosine phosphatases: Molecular switches in metabolism and diabetes

Trends in Endocrinology and Metabolism

Volumn 26, Issue 1, 2015, Pages 30-39

  Gurzov, Esteban N ^a,b   Stanley, William J ^a,b   Brodnicki, Thomas C ^a   Thomas, Helen E ^a,b  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Metabolism; Protein tyrosine phosphatases; Type 1 diabetes; Type 2 diabetes

Indexed keywords

LEPTIN; PROTEIN TYROSINE PHOSPHATASE;

ADIPOSE TISSUE; B LYMPHOCYTE; CELL FUNCTION; DIABETES MELLITUS; ENERGY BALANCE; GENETIC POLYMORPHISM; HOMEOSTASIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; ANIMAL; CELLULAR IMMUNITY; CHEMICAL STRUCTURE; ENERGY METABOLISM; GENETICS; IMMUNOLOGY; PANCREAS ISLET BETA CELL; PHYSIOLOGY; REGULATOR GENE;

ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; GENES, SWITCH; HUMANS; IMMUNITY, CELLULAR; INSULIN-SECRETING CELLS; METABOLISM; MODELS, MOLECULAR; POLYMORPHISM, GENETIC; PROTEIN TYROSINE PHOSPHATASES;

EID: 84920435510     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2014.10.004     Document Type: Review

References (100)

1. Tonks N.K. Protein tyrosine phosphatases - from housekeeping enzymes to master regulators of signal transduction. FEBS J. 2013, 280:346-378.
2. Wang W.Q., et al. An overview of the protein tyrosine phosphatase superfamily. Curr. Top. Med. Chem. 2003, 3:739-748.
3. St-Pierre J., Tremblay M.L. Modulation of leptin resistance by protein tyrosine phosphatases. Cell Metab. 2012, 15:292-297.
4. Torii S. Expression and function of IA-2 family proteins, unique neuroendocrine-specific protein-tyrosine phosphatases. Endocr. J. 2009, 56:639-648.
5. Ortega-Molina A., Serrano M. PTEN in cancer, metabolism, and aging. Trends Endocrinol. Metab. 2013, 24:184-189.
6. Alonso A., et al. Protein tyrosine phosphatases in the human genome. Cell 2004, 117:699-711.
7. Andersen J.N., et al. Computational analysis of protein tyrosine phosphatases: practical guide to bioinformatics and data resources. Methods 2005, 35:90-114.
8. Smyth D., et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 2004, 53:3020-3023.
9. Zheng W., She J.X. Genetic association between a lymphoid tyrosine phosphatase (PTPN22) and type 1 diabetes. Diabetes 2005, 54:906-908.
10. Qu H., et al. Confirmation of the association of the R620W polymorphism in the protein tyrosine phosphatase PTPN22 with type 1 diabetes in a family based study. J. Med. Genet. 2005, 42:266-270.
11. Onengut-Gumuscu S., et al. A haplotype-based analysis of the PTPN22 locus in type 1 diabetes. Diabetes 2006, 55:2883-2889.
12. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661-678. Wellcome Trust Case Control Consortium.
13. Zoledziewska M., et al. Further evidence of a primary, causal association of the PTPN22 620W variant with type 1 diabetes. Diabetes 2008, 57:229-234.
14. Espino-Paisan L., et al. A polymorphism in PTPN2 gene is associated with an earlier onset of type 1 diabetes. Immunogenetics 2011, 63:255-258.
15. Barrett J.C., et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat. Genet. 2009, 41:703-707.
16. Tsou R.C., Bence K.K. The genetics of PTPN1 and obesity: insights from mouse models of tissue-specific PTP1B deficiency. J. Obes. 2012, 2012:926857.
17. Eizirik D.L., et al. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat. Rev. Endocrinol. 2009, 5:219-226.
18. Thomas H.E., et al. Interferon signalling in pancreatic beta cells. Front. Biosci. 2009, 14:644-656.
19. Kim S., et al. Essential role for signal transducer and activator of transcription-1 in pancreatic beta-cell death and autoimmune type 1 diabetes of nonobese diabetic mice. Diabetes 2007, 56:2561-2568.
20. Gysemans C.A., et al. Disruption of the gamma-interferon signaling pathway at the level of signal transducer and activator of transcription-1 prevents immune destruction of beta-cells. Diabetes 2005, 54:2396-2403.
21. Chong M.M., et al. Suppressor of cytokine signaling-1 overexpression protects pancreatic beta cells from CD8+ T cell-mediated autoimmune destruction. J. Immunol. 2004, 172:5714-5721.
22. Moore F., et al. PTPN2, a candidate gene for type 1 diabetes, modulates interferon-gamma-induced pancreatic beta-cell apoptosis. Diabetes 2009, 58:1283-1291.
23. Santin I., et al. PTPN2, a candidate gene for type 1 diabetes, modulates pancreatic beta-cell apoptosis via regulation of the BH3-only protein Bim. Diabetes 2011, 60:3279-3288.
24. Barthson J., et al. Cytokines tumor necrosis factor-alpha and interferon-gamma induce pancreatic beta-cell apoptosis through STAT1-mediated Bim protein activation. J. Biol. Chem. 2011, 286:39632-39643.
25. Marroqui L., et al. BACH2, a candidate risk gene for type 1 diabetes, regulates apoptosis in pancreatic beta-cells via JNK1 modulation and crosstalk with the candidate gene PTPN2. Diabetes 2014, 63:2516-2527.
26. Wiede F., et al. T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice. J. Clin. Invest. 2011, 121:4758-4774.
27. Wiede F., et al. PTPN2 restrains CD8 T cell responses after antigen cross-presentation for the maintenance of peripheral tolerance in mice. J. Autoimmun. 2014, 53:105-114.
28. Fousteri G., et al. Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunity. Clin. Immunol. 2013, 149:556-565.
29. Cloutier J.F., Veillette A. Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J. Exp. Med. 1999, 189:111-121.
30. Yeh L.T., et al. Different modulation of Ptpn22 in effector and regulatory T cells leads to attenuation of autoimmune diabetes in transgenic nonobese diabetic mice. J. Immunol. 2013, 191:594-607.
31. Zheng P., Kissler S. PTPN22 silencing in the NOD model indicates the type 1 diabetes-associated allele is not a loss-of-function variant. Diabetes 2013, 62:896-904.
32. Zikherman J., et al. PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background. J. Immunol. 2009, 182:4093-4106.
33. Zhang J., et al. The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat. Genet. 2011, 43:902-907.
34. Cao Y., et al. High basal activity of the PTPN22 gain-of-function variant blunts leukocyte responsiveness negatively affecting IL-10 production in ANCA vasculitis. PLoS ONE 2012, 7:e42783.
35. Habib T., et al. Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant. J. Immunol. 2012, 188:487-496.
36. Dai X., et al. A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. J. Clin. Invest. 2013, 123:2024-2036.
37. Gurzov E.N., Eizirik D.L. Bcl-2 proteins in diabetes: mitochondrial pathways of beta-cell death and dysfunction. Trends Cell Biol. 2011, 21:424-431.
38. Bettaieb A., et al. Differential regulation of endoplasmic reticulum stress by protein tyrosine phosphatase 1B and T cell protein tyrosine phosphatase. J. Biol. Chem. 2011, 286:9225-9235.
39. Lu B., et al. Improved glucose-stimulated insulin secretion by intra-islet inhibition of protein-tyrosine phosphatase 1B expression in rats fed a high-fat diet. J. Endocrinol. Invest. 2012, 35:63-70.
40. Kushner J.A., et al. Islet-sparing effects of protein tyrosine phosphatase-1b deficiency delays onset of diabetes in IRS2 knockout mice. Diabetes 2004, 53:61-66.
41. Fernandez-Ruiz R., et al. Protein tyrosine phosphatase-1B modulates pancreatic beta-cell mass. PLoS ONE 2014, 9:e90344.
42. Liu S., et al. Disruption of protein-tyrosine phosphatase 1B expression in the pancreas affects beta-cell function. Endocrinology 2014, 155:3329-3338.
43. Welters H.J., et al. The protein tyrosine phosphatase-BL, modulates pancreatic beta-cell proliferation by interaction with the Wnt signalling pathway. J. Endocrinol. 2008, 197:543-552.
44. Wansink D.G., et al. Mild impairment of motor nerve repair in mice lacking PTP-BL tyrosine phosphatase activity. Physiol. Genomics 2004, 19:50-60.
45. Myers M.G., et al. Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol. Metab. 2010, 21:643-651.
46. Zabolotny J.M., et al. PTP1B regulates leptin signal transduction in vivo. Dev. Cell 2002, 2:489-495.
47. Kaszubska W., et al. Protein tyrosine phosphatase 1B negatively regulates leptin signaling in a hypothalamic cell line. Mol. Cell. Endocrinol. 2002, 195:109-118.
48. Bence K.K., et al. Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat. Med. 2006, 12:917-924.
49. Banno R., et al. PTP1B and SHP2 in POMC neurons reciprocally regulate energy balance in mice. J. Clin. Invest. 2010, 120:720-734.
50. Xue B., et al. Neuronal protein tyrosine phosphatase 1B deficiency results in inhibition of hypothalamic AMPK and isoform-specific activation of AMPK in peripheral tissues. Mol. Cell. Biol. 2009, 29:4563-4573.
51. Cheng A., et al. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev. Cell 2002, 2:497-503.
52. Tsou R.C., et al. Deficiency of PTP1B in leptin receptor-expressing neurons leads to decreased body weight and adiposity in mice. Endocrinology 2012, 153:4227-4237.
53. Chiappini F., et al. Ventromedial hypothalamus-specific Ptpn1 deletion exacerbates diet-induced obesity in female mice. J. Clin. Invest. 2014, 124:3781-3792.
54. Loh K., et al. Elevated hypothalamic TCPTP in obesity contributes to cellular leptin resistance. Cell Metab. 2011, 14:684-699.
55. Krajewska M., et al. Development of diabesity in mice with neuronal deletion of Shp2 tyrosine phosphatase. Am. J. Pathol. 2008, 172:1312-1324.
56. He Z., et al. Shp2 controls female body weight and energy balance by integrating leptin and estrogen signals. Mol. Cell. Biol. 2012, 32:1867-1878.
57. Faure R., et al. The dephosphorylation of insulin and epidermal growth factor receptors. Role of endosome-associated phosphotyrosine phosphatase(s). J. Biol. Chem. 1992, 267:11215-11221.
58. Elchebly M., et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999, 283:1544-1548.
59. Egawa K., et al. Protein-tyrosine phosphatase-1B negatively regulates insulin signaling in l6 myocytes and Fao hepatoma cells. J. Biol. Chem. 2001, 276:10207-10211.
60. Haj F.G., et al. Liver-specific protein-tyrosine phosphatase 1B (PTP1B) re-expression alters glucose homeostasis of PTP1B-/-mice. J. Biol. Chem. 2005, 280:15038-15046.
61. Clampit J.E., et al. Reduction of protein-tyrosine phosphatase-1B increases insulin signaling in FAO hepatoma cells. Biochem. Biophys. Res. Commun. 2003, 300:261-267.
62. Gum R.J., et al. Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice. Diabetes 2003, 52:21-28.
63. Delibegovic M., et al. Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress. Diabetes 2009, 58:590-599.
64. Dubois M.J., et al. The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis. Nat. Med. 2006, 12:549-556.
65. Xu E., et al. Hepatocyte-specific Ptpn6 deletion protects from obesity-linked hepatic insulin resistance. Diabetes 2012, 61:1949-1958.
66. Xu E., et al. Hepatocyte-specific Ptpn6 deletion promotes hepatic lipid accretion, but reduces NAFLD in diet-induced obesity: potential role of PPARgamma. Hepatology 2014, 59:1803-1815.
67. Oriente F., et al. Prep1 controls insulin glucoregulatory function in liver by transcriptional targeting of SHP1 tyrosine phosphatase. Diabetes 2011, 60:138-147.
68. Nagata N., et al. Hepatic Src homology phosphatase 2 regulates energy balance in mice. Endocrinology 2012, 153:3158-3169.
69. Matsuo K., et al. Altered glucose homeostasis in mice with liver-specific deletion of Src homology phosphatase 2. J. Biol. Chem. 2010, 285:39750-39758.
70. Cho C.Y., et al. Identification of the tyrosine phosphatase PTP-MEG2 as an antagonist of hepatic insulin signaling. Cell Metab. 2006, 3:367-378.
71. Fukushima A., et al. T-cell protein tyrosine phosphatase attenuates STAT3 and insulin signaling in the liver to regulate gluconeogenesis. Diabetes 2010, 59:1906-1914.
72. Gurzov E.N., et al. Hepatic oxidative stress promotes onsulin-STAT-5 signaling and obesity by inactivating protein tyrosine phosphatase N2. Cell Metab. 2014, 20:85-102.
73. Rasmussen M.H. Obesity, growth hormone and weight loss. Mol. Cell. Endocrinol. 2010, 316:147-153.
74. Pilecka I., et al. Protein-tyrosine phosphatase H1 controls growth hormone receptor signaling and systemic growth. J. Biol. Chem. 2007, 282:35405-35415.
75. Pasquali C., et al. Identification of protein tyrosine phosphatases with specificity for the ligand-activated growth hormone receptor. Mol. Endocrinol. 2003, 17:2228-2239.
76. Bauler T.J., et al. The FERM and PDZ domain-containing protein tyrosine phosphatases, PTPN4 and PTPN3, are both dispensable for T cell receptor signal transduction. PLoS ONE 2008, 3:e4014.
77. Elbein S.C., et al. Global gene expression profiles of subcutaneous adipose and muscle from glucose-tolerant, insulin-sensitive, and insulin-resistant individuals matched for BMI. Diabetes 2011, 60:1019-1029.
78. Ahmad F., et al. Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J. Clin. Invest. 1997, 100:449-458.
79. Ahmad F., et al. Improved sensitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatases in adipose tissue. Metabolism 1997, 46:1140-1145.
80. Ikeda Y., et al. Protein tyrosine phosphatase 1B is impaired in skeletal muscle of diabetic Psammomys obesus. Int. J. Exp. Diabetes Res. 2002, 3:205-212.
81. Delibegovic M., et al. Improved glucose homeostasis in mice with muscle-specific deletion of protein-tyrosine phosphatase 1B. Mol. Cell. Biol. 2007, 27:7727-7734.
82. Ali M.I., et al. Deletion of protein tyrosine phosphatase 1b improves peripheral insulin resistance and vascular function in obese, leptin-resistant mice via reduced oxidant tone. Circ. Res. 2009, 105:1013-1022.
83. Zabolotny J.M., et al. Transgenic overexpression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action. J. Biol. Chem. 2004, 279:24844-24851.
84. Owen C., et al. Adipocyte-specific protein tyrosine phosphatase 1B deletion increases lipogenesis, adipocyte cell size and is a minor regulator of glucose homeostasis. PLoS ONE 2012, 7:e32700.
85. Princen F., et al. Deletion of Shp2 tyrosine phosphatase in muscle leads to dilated cardiomyopathy, insulin resistance, and premature death. Mol. Cell. Biol. 2009, 29:378-388.
86. Maegawa H., et al. Expression of a dominant negative SHP-2 in transgenic mice induces insulin resistance. J. Biol. Chem. 1999, 274:30236-30243.
87. Bettaieb A., et al. Adipose-specific deletion of Src homology phosphatase 2 does not significantly alter systemic glucose homeostasis. Metab. Clin. Exp. 2011, 60:1193-1201.
88. He Z., et al. Nonreceptor tyrosine phosphatase Shp2 promotes adipogenesis through inhibition of p38 MAP kinase. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E79-E88.
89. Heneberg P. Use of protein tyrosine phosphatase inhibitors as promising targeted therapeutic drugs. Curr. Med. Chem. 2009, 16:706-733.
90. Zhang S., et al. A highly selective and potent PTP-MEG2 inhibitor with therapeutic potential for type 2 diabetes. J. Am. Chem. Soc. 2012, 134:18116-18124.
91. Barr A.J. Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development. Future Med. Chem. 2010, 2:1563-1576.
92. Xie L., et al. Cellular effects of small molecule PTP1B inhibitors on insulin signaling. Biochemistry 2003, 42:12792-12804.
93. Morrison C.D., et al. Increased hypothalamic protein tyrosine phosphatase 1B contributes to leptin resistance with age. Endocrinology 2007, 148:433-440.
94. Brandao T.A., et al. Insights into the reaction of protein-tyrosine phosphatase 1B: crystal structures for transition state analogs of both catalytic steps. J. Biol. Chem. 2010, 285:15874-15883.
95. Sun J.P., et al. Crystal structure of the Yersinia protein-tyrosine phosphatase YopH complexed with a specific small molecule inhibitor. J. Biol. Chem. 2003, 278:33392-33399.
96. Jia Z., et al. Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase 1B. Science 1995, 268:1754-1758.
97. Tonks N.K. Redox redux: revisiting PTPs and the control of cell signaling. Cell 2005, 121:667-670.
98. Ostman A., et al. Regulation of protein tyrosine phosphatases by reversible oxidation. J. Biochem. 2011, 150:345-356.
99. Loh K., et al. Reactive oxygen species enhance insulin sensitivity. Cell Metab. 2009, 10:260-272.
100. Brown M.S., Goldstein J.L. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008, 7:95-96.